KRAS and non-small cell lung carcinoma: For example, preclinical findings have identified that inhibition of the interleukin-6 (IL-6)/STAT3 pathway can also inhibit tumor growth with EGFR mutation in NSCLC and suppress KRAS-driven lung adenocarcinoma (82–85).